MA30556B1 - COMPOSES A BASE DE DIALKYLPHENYLE AYANT UNE ACTIVITE AGONISTE DU RECEPTEUR ADRENERGIQUE ß2 ET ANTAGONISTE DU RECEPTEUR MUSCARINIQUE. - Google Patents

COMPOSES A BASE DE DIALKYLPHENYLE AYANT UNE ACTIVITE AGONISTE DU RECEPTEUR ADRENERGIQUE ß2 ET ANTAGONISTE DU RECEPTEUR MUSCARINIQUE.

Info

Publication number
MA30556B1
MA30556B1 MA31382A MA31382A MA30556B1 MA 30556 B1 MA30556 B1 MA 30556B1 MA 31382 A MA31382 A MA 31382A MA 31382 A MA31382 A MA 31382A MA 30556 B1 MA30556 B1 MA 30556B1
Authority
MA
Morocco
Prior art keywords
receptor
dialkylphenyl
antagonist
based compounds
compounds
Prior art date
Application number
MA31382A
Other languages
English (en)
Inventor
Pierre-Jean Colson
Adam Hughes
Craig Husfeld
Mathai Mammen
Miroslav Rapta
Original Assignee
Theravance Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Theravance Inc filed Critical Theravance Inc
Publication of MA30556B1 publication Critical patent/MA30556B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

La présente invention concerne des composés de formule I, dans laquelle: R1 et R2 sont tels que définis dans la spécification, ou un sel ou solvate ou stéréoisomère pharmaceutiquement acceptable de celui-ci. L'invention concerne également des compositions et combinaisons pharmaceutiques comportant de tels composés, des procédés et des intermédiaires pour préparer de tels composés, et des procédés d'utilisation de tels composés par exemple, pour traiter des troubles pulmonaires, tels que la maladie pulmonaire obstructive chronique et l'asthme.
MA31382A 2006-04-25 2008-11-14 COMPOSES A BASE DE DIALKYLPHENYLE AYANT UNE ACTIVITE AGONISTE DU RECEPTEUR ADRENERGIQUE ß2 ET ANTAGONISTE DU RECEPTEUR MUSCARINIQUE. MA30556B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US79470206P 2006-04-25 2006-04-25

Publications (1)

Publication Number Publication Date
MA30556B1 true MA30556B1 (fr) 2009-07-01

Family

ID=38577470

Family Applications (1)

Application Number Title Priority Date Filing Date
MA31382A MA30556B1 (fr) 2006-04-25 2008-11-14 COMPOSES A BASE DE DIALKYLPHENYLE AYANT UNE ACTIVITE AGONISTE DU RECEPTEUR ADRENERGIQUE ß2 ET ANTAGONISTE DU RECEPTEUR MUSCARINIQUE.

Country Status (20)

Country Link
US (3) US7524965B2 (fr)
EP (1) EP2010489B1 (fr)
JP (1) JP2009541209A (fr)
KR (1) KR20090005389A (fr)
CN (1) CN101426764A (fr)
AR (1) AR060647A1 (fr)
AU (1) AU2007243481A1 (fr)
BR (1) BRPI0710767A2 (fr)
CA (1) CA2650530A1 (fr)
CO (1) CO6140054A2 (fr)
ES (1) ES2391584T3 (fr)
IL (1) IL194334A0 (fr)
MA (1) MA30556B1 (fr)
MX (1) MX2008013555A (fr)
NO (1) NO20084603L (fr)
PE (1) PE20080094A1 (fr)
RU (1) RU2008146383A (fr)
TW (1) TW200811105A (fr)
WO (1) WO2007127196A2 (fr)
ZA (1) ZA200808817B (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6693202B1 (en) * 1999-02-16 2004-02-17 Theravance, Inc. Muscarinic receptor antagonists
PE20040950A1 (es) 2003-02-14 2005-01-01 Theravance Inc DERIVADOS DE BIFENILO COMO AGONISTAS DE LOS RECEPTORES ADRENERGICOS ß2 Y COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS
TWI341836B (en) 2004-03-11 2011-05-11 Theravance Inc Biphenyl compounds useful as muscarinic receptor antagonists
WO2006023457A1 (fr) * 2004-08-16 2006-03-02 Theravance, Inc. Composes a activite agoniste pour recepteur ?2 adrenergique et antagoniste pour recepteur muscarinique
TW200811104A (en) * 2006-04-25 2008-03-01 Theravance Inc Crystalline forms of a dimethylphenyl compound
TW200811105A (en) * 2006-04-25 2008-03-01 Theravance Inc Dialkylphenyl compounds having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity
CN102083839B (zh) * 2008-02-06 2014-03-26 阿斯利康(瑞典)有限公司 化合物
LT2599778T (lt) 2009-04-23 2017-08-25 Theravance Respiratory Company, Llc Diamido junginiai, pasižymintys muskarininiam receptoriui antagonistiniu ir beta 2 adrenerginiam receptoriui agonistiniu aktyvumu
US20110020423A1 (en) 2009-07-22 2011-01-27 Puretech Ventures Methods and compositions for treatment of disorders ameliorated by muscarinic receptor activation
US10265311B2 (en) 2009-07-22 2019-04-23 PureTech Health LLC Methods and compositions for treatment of disorders ameliorated by muscarinic receptor activation
WO2011081937A1 (fr) 2009-12-15 2011-07-07 Gilead Sciences, Inc. Composés de type corticostéroïde-bêta-agoniste-antagoniste muscarinique pour applications thérapeutiques
GB201009801D0 (en) 2010-06-11 2010-07-21 Astrazeneca Ab Compounds 950
CA3180743A1 (fr) 2018-09-28 2020-04-02 Karuna Therapeutics, Inc. Composition comprenant de la xanomeline et du trospium pour le traitement de troubles ameliores par l'activation du recepteur muscarinique
CN114409556B (zh) * 2022-01-28 2024-10-18 兰州康鹏威耳化工有限公司 一种3,4-二取代-2-氨基苯甲醛的制备方法
CN117924216A (zh) * 2024-01-12 2024-04-26 王叔和生物医药(武汉)有限公司 一种1-哌啶丙酸的合成方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7545894A (en) 1993-09-02 1995-03-22 Yamanouchi Pharmaceutical Co., Ltd. Carbamate derivative and medicine containing the same
EP0747355A4 (fr) 1994-02-10 1997-04-09 Yamanouchi Pharma Co Ltd Nouveau derive du carbamate et composition correspondante
US6040344A (en) 1996-11-11 2000-03-21 Sepracor Inc. Formoterol process
US6541669B1 (en) * 1998-06-08 2003-04-01 Theravance, Inc. β2-adrenergic receptor agonists
US6693202B1 (en) 1999-02-16 2004-02-17 Theravance, Inc. Muscarinic receptor antagonists
DE19921693A1 (de) 1999-05-12 2000-11-16 Boehringer Ingelheim Pharma Neuartige Arzneimittelkompositionen auf der Basis von anticholinergisch wirksamen Verbindungen und ß-Mimetika
UA73965C2 (en) 1999-12-08 2005-10-17 Theravance Inc b2 ADRENERGIC RECEPTOR ANTAGONISTS
WO2002076933A1 (fr) 2001-03-22 2002-10-03 Glaxo Group Limited Derives formanilides utilises en tant qu'agonistes de l'adrenorecepteur beta2
US20030018019A1 (en) 2001-06-23 2003-01-23 Boehringer Ingelheim Pharma Kg Pharmaceutical compositions based on anticholinergics, corticosteroids and betamimetics
TWI249515B (en) 2001-11-13 2006-02-21 Theravance Inc Aryl aniline beta2 adrenergic receptor agonists
PE20040950A1 (es) * 2003-02-14 2005-01-01 Theravance Inc DERIVADOS DE BIFENILO COMO AGONISTAS DE LOS RECEPTORES ADRENERGICOS ß2 Y COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS
CA2543858C (fr) 2003-11-21 2014-04-15 Theravance, Inc. Composes ayant une activite agoniste de recepteur adrenergique beta 2 et antagoniste de recepteur muscarinique
US7456199B2 (en) 2004-03-11 2008-11-25 Theravance, Inc. Biphenyl compounds useful as muscarinic receptor antagonists
WO2006023457A1 (fr) 2004-08-16 2006-03-02 Theravance, Inc. Composes a activite agoniste pour recepteur ?2 adrenergique et antagoniste pour recepteur muscarinique
EP1833822A2 (fr) 2004-08-16 2007-09-19 Theravance, Inc. Composes a activite agoniste pour recepteur beta2 adrenergique et antagoniste pour recepteur muscarinique
TWI374883B (en) 2004-08-16 2012-10-21 Theravance Inc Crystalline form of a biphenyl compound
TW200811104A (en) * 2006-04-25 2008-03-01 Theravance Inc Crystalline forms of a dimethylphenyl compound
TW200811105A (en) 2006-04-25 2008-03-01 Theravance Inc Dialkylphenyl compounds having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity

Also Published As

Publication number Publication date
RU2008146383A (ru) 2010-05-27
PE20080094A1 (es) 2008-02-17
WO2007127196A3 (fr) 2007-12-21
US8134006B2 (en) 2012-03-13
ZA200808817B (en) 2010-03-31
CA2650530A1 (fr) 2007-11-08
ES2391584T3 (es) 2012-11-28
TW200811105A (en) 2008-03-01
US20100137603A1 (en) 2010-06-03
CN101426764A (zh) 2009-05-06
US7687521B2 (en) 2010-03-30
EP2010489A2 (fr) 2009-01-07
MX2008013555A (es) 2008-11-04
US20090176833A1 (en) 2009-07-09
BRPI0710767A2 (pt) 2011-06-07
IL194334A0 (en) 2009-08-03
JP2009541209A (ja) 2009-11-26
CO6140054A2 (es) 2010-03-19
EP2010489B1 (fr) 2012-08-22
US7524965B2 (en) 2009-04-28
AR060647A1 (es) 2008-07-02
WO2007127196A2 (fr) 2007-11-08
AU2007243481A1 (en) 2007-11-08
KR20090005389A (ko) 2009-01-13
US20070249675A1 (en) 2007-10-25
NO20084603L (no) 2008-11-19

Similar Documents

Publication Publication Date Title
MA30556B1 (fr) COMPOSES A BASE DE DIALKYLPHENYLE AYANT UNE ACTIVITE AGONISTE DU RECEPTEUR ADRENERGIQUE ß2 ET ANTAGONISTE DU RECEPTEUR MUSCARINIQUE.
WO2006023460A3 (fr) Composes a activite agoniste pour recepteur ?2 adrenergique et antagoniste pour recepteur muscarinique
US7582672B2 (en) Compounds for the treatment of CRTH2-mediated diseases and conditions
TNSN07349A1 (fr) Derives de n-(n-sulfonylaminomethyl) cyclopropanecarboxamide utiles pour le traitement de la douleur
MY158339A (en) DIAMIDE COMPOUNDS HAVING MUSCARING RECEPTOR ANTAGONIST AND ß2 ADRENERGIC RECEPTOR AGONIST ACTIVITY
WO2004074246A3 (fr) Derives de biphenyle
MA31311B1 (fr) Dérivés d'indazole substitués par oxadiazole, destinés à être utilisés comme agonistes de la sphingosine 1-phosphate (s1p)
MA28432B1 (fr) Antagonistes du recepteur de la chimiokine
EP2552433A2 (fr) Compositions et procédés pour le traitement de troubles somatosensoriels
MA27779A1 (fr) FORME CRISTALLINE D'AGONISTE DE RECEPTEUR β2 ADRENERGIQUE
MA28435B1 (fr) Composes d'indazole-carboxamide en tant qu'agonistes de recepteur 5-ht4
WO2004089892A3 (fr) Diarylmethyle et composes apparentes
MA30284B1 (fr) Composes de 8-azabicyclo[3.2.1]octane en tant qu'antagonistes du recepteur opioide mu
WO2009063215A2 (fr) Utilisation de composés antagonistes de crth2
JP2011503045A (ja) Ｃｒｔｈ２拮抗化合物の使用
SI1735278T1 (sl) Agenti histamin h receptorja priprava in terapevtska uporaba
NO20075453L (no) Sammensetning inneholdende antidemensmiddel
PH12014500937A1 (en) 5-ht 1a receptor substype agonist
EA200701361A1 (ru) Конденсированные производные пиразола и способы лечения с их помощью заболеваний, вызванных нарушением обмена веществ
MA29541B1 (fr) Composes benzimidazole-carboxamide utilises comme agonistes du recepteur 5-ht4
CN1491223A (zh) 可用于治疗精神性和神经性疾病的3-二氢吲哚衍生物
CY1109694T1 (el) Παραγωγα πυρρολιδινης ως ανταγωνιστες υποδοχεα η3 ισταμινης
WO2006038006A3 (fr) Nouveaux composes
EA200601461A1 (ru) Новые производные бензил(иден)лактама
EP1115404B1 (fr) Utilisation d'antagonistes de prostanoides pour le traitement de cephalees primaires